Busarin Arunsak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Busarin Arunsak has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Titikorn Chunchai
Neurophysiology unit, Cardiac electrophysiology research and training center, Faculty of medicine, Chiang Mai University, Chiang Mai, Thailand
17 shared publications - Nipon Chattipakorn
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
15 shared publications - Nattayaporn Apaijai
Chiang Mai University
11 shared publications - Siriporn C. Chattipakorn
Neurophysiology unit, Cardiac electrophysiology research and training center, Faculty of medicine, Chiang Mai University, Chiang Mai, Thailand
11 shared publications - Benjamin Ongnok
Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai Thailand
10 shared publications Sasiwan Kerdphoo
Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai Thailand
8 shared publications
Latest Publications
- 6 March 2026
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 29 (9) , 1-17
Prebiotic-based banana snacks ( Musa sapientum L.) alleviate cognitive impairment by reducing brain inflammation, apoptosis, microglial activation, and dendritic spine loss in obese rats
Prebiotics may reduce adiposity and inflammation, improving cognitive function in obese rats, mediated by modulation of the gut-brain axis. Banana-based snacks are promising prebiotic foods. However, their effects on gut microbiota, inflammation, brain reactive oxygen species (ROS) production, microglial morphology, dendritic spine density, and cognitive function remain underexplored in high-fat diet (HFD)-induced obese rats. Seventy-two male rats were maintained on either a normal diet (ND) or a HFD for 16-weeks. At week 13, ND-fed rats were subdivided into six groups (n = 6/group) receiving either a vehicle (NDV, 10.5 mL/kg/day twice daily), prebiotic snacks from bananas at ripening stages 2-5 (NDS2-5, 7.47 g in water, 10.5 mL/kg/day twice daily), or inulin (NDI, 2 g/kg/day in water, 10.5 mL/kg/day twice daily). HFD-fed rats were similarly subdivided into six groups (n = 6/group) with either a vehicle (HFV), banana-based prebiotic snacks (HFS2-5), or inulin (HFI), administered for four weeks at the same doses as the ND-fed rats. HFD-fed rats exhibited both obesity and insulin resistance, gut dysbiosis, inflammation, and cognitive impairment. However, rats receiving inulin or banana-based prebiotics from all ripening stages exhibited improved cognitive function by reducing gut dysbiosis, oxidative stress, inflammation, brain ROS, apoptosis, dendritic spine loss, and microglial activation. Prebiotic banana snacks from all ripening stages may protect against HFD-induced cognitive impairment by enhancing gut health and reducing inflammation and oxidative stress, potentially via the gut-brain axis. These findings support their potential use as functional foods to promote both cognitive and metabolic health.
- 6 March 2026
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 29 (9) , 1-17
Prebiotic-based banana snacks ( Musa sapientum L.) alleviate cognitive impairment by reducing brain inflammation, apoptosis, microglial activation, and dendritic spine loss in obese rats
Prebiotics may reduce adiposity and inflammation, improving cognitive function in obese rats, mediated by modulation of the gut-brain axis. Banana-based snacks are promising prebiotic foods. However, their effects on gut microbiota, inflammation, brain reactive oxygen species (ROS) production, microglial morphology, dendritic spine density, and cognitive function remain underexplored in high-fat diet (HFD)-induced obese rats. Seventy-two male rats were maintained on either a normal diet (ND) or a HFD for 16-weeks. At week 13, ND-fed rats were subdivided into six groups (n = 6/group) receiving either a vehicle (NDV, 10.5 mL/kg/day twice daily), prebiotic snacks from bananas at ripening stages 2-5 (NDS2-5, 7.47 g in water, 10.5 mL/kg/day twice daily), or inulin (NDI, 2 g/kg/day in water, 10.5 mL/kg/day twice daily). HFD-fed rats were similarly subdivided into six groups (n = 6/group) with either a vehicle (HFV), banana-based prebiotic snacks (HFS2-5), or inulin (HFI), administered for four weeks at the same doses as the ND-fed rats. HFD-fed rats exhibited both obesity and insulin resistance, gut dysbiosis, inflammation, and cognitive impairment. However, rats receiving inulin or banana-based prebiotics from all ripening stages exhibited improved cognitive function by reducing gut dysbiosis, oxidative stress, inflammation, brain ROS, apoptosis, dendritic spine loss, and microglial activation. Prebiotic banana snacks from all ripening stages may protect against HFD-induced cognitive impairment by enhancing gut health and reducing inflammation and oxidative stress, potentially via the gut-brain axis. These findings support their potential use as functional foods to promote both cognitive and metabolic health.
- 27 December 2023
- Published by Springer Nature in Molecular Neurobiology
- Vol. 61 (7) , 4879-4890
Cyclosorus Terminans Extract Alleviates Neuroinflammation in Insulin Resistant Rats
High-fat diet consumption for an extended period causes obesity, systemic metabolic disturbance, and brain insulin resistance, resulting in neuroinflammation. Although the beneficial effect of Cyclosorus terminans extract on obesity-related insulin resistance has been demonstrated, little is known about how it affects neuroinflammation and brain insulin resistance in obese rats. Male Wistar rats were given either a normal diet (ND, n = 6) or a high-fat diet (HFD, n = 24) for a total of 14 weeks. At the beginning of the week, 13 rats in the ND group were given vehicle orally for 2 weeks, while rats on HFD diets were randomized to one of four groups and given either vehicle, 100 mg/kg/day of Cyclosorus terminans extract, 200 mg/kg/day of Cyclosorus terminans extract, or 20 mg/kg/day of pioglitazone orally for 2 weeks. After the experimental period, blood and brain samples were taken to assess metabolic and brain parameters. HFD-fed rats had obesity, systemic and brain insulin resistance, brain inflammation, microglial and astrocyte hyperactivity, and brain necroptosis. Treatment with 200 mg/kg/day of Cyclosorus terminans extract and pioglitazone equally attenuated obesity, insulin resistance, brain insulin dysfunction, and neuroinflammation in insulin resistant rats. Our findings suggest that Cyclosorus terminans extract may hold promise as a therapeutic agent for insulin resistance and neuroinflammation in obese conditions.
- 27 December 2023
- Published by Springer Nature in Molecular Neurobiology
- Vol. 61 (7) , 4879-4890
Cyclosorus Terminans Extract Alleviates Neuroinflammation in Insulin Resistant Rats
High-fat diet consumption for an extended period causes obesity, systemic metabolic disturbance, and brain insulin resistance, resulting in neuroinflammation. Although the beneficial effect of Cyclosorus terminans extract on obesity-related insulin resistance has been demonstrated, little is known about how it affects neuroinflammation and brain insulin resistance in obese rats. Male Wistar rats were given either a normal diet (ND, n = 6) or a high-fat diet (HFD, n = 24) for a total of 14 weeks. At the beginning of the week, 13 rats in the ND group were given vehicle orally for 2 weeks, while rats on HFD diets were randomized to one of four groups and given either vehicle, 100 mg/kg/day of Cyclosorus terminans extract, 200 mg/kg/day of Cyclosorus terminans extract, or 20 mg/kg/day of pioglitazone orally for 2 weeks. After the experimental period, blood and brain samples were taken to assess metabolic and brain parameters. HFD-fed rats had obesity, systemic and brain insulin resistance, brain inflammation, microglial and astrocyte hyperactivity, and brain necroptosis. Treatment with 200 mg/kg/day of Cyclosorus terminans extract and pioglitazone equally attenuated obesity, insulin resistance, brain insulin dysfunction, and neuroinflammation in insulin resistant rats. Our findings suggest that Cyclosorus terminans extract may hold promise as a therapeutic agent for insulin resistance and neuroinflammation in obese conditions.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
A single dose of lipopolysaccharide injection exacerbates synaptic engulfment by microglia, and dendritic spine loss in high‐fat diet‐induced obese rats
Background: Diet‐induced obesity can lead to develop endotoxemia and cognitive decline (1). A previous study in Alzheimer’s disease model demonstrated that an increase in the colocalization of C1q, a classical complement protein, and microglia occurred, when those microglia increased synaptic engulfment, resulting in increased synaptic‐pruning process and synaptic loss (2). However, the effects of lipopolysaccharide (LPS) as endotoxin on peripheral inflammation, blood‐brain barrier(BBB) integrity, brain oxidative stress, synaptic engulfment by microglia, synaptic plasticity, and cognitive function in high‐fat diet‐induced obese rats have never been investigated.Method: Sixteen male Wistar rats were randomly assigned to receive either a normal diet (ND, n = 8) or the high‐fat diet (HFD, n = 8) for 12 weeks. All animals in each dietary group were subsequently assigned into 2 subgroups (n = 4 /subgroup) to receive either a single dose of vehicle (1 ml of 0.9% normal saline solution, intraperitoneal (i.p.) injection, or LPS (0.5 mg/kg, i.p.). After the injections for 12‐16 hours, all animals were measured for cognitive function and the blood was collected. Then, animals were sacrificed, and their brains and spleens were obtained for further investigation.Result: All HFD‐fed rats exhibited peripheral inflammation as indicated by increased spleen IL‐1β protein levels, BBB disruption as indicated by the reduction of hippocampal claudia‐5 protein levels, and increased brain oxidative stress as indicated by the increased brain malondialdehyde levels (pFigure 1). Interestingly, LPS‐treated ND‐fed rats and vehicle‐treated HFD‐fed rats equally impaired microglial function by increasing synaptic engulfment as indicated by the increase in C1q colocalized in microglia and the decreased dendritic spine density (pFigure 1). The results demonstrated that these parameters were aggravated in LPS‐treated HFD‐fed rats. Lastly, all HFD‐fed rats decreased the preference index of novel object location and recognition test suggesting long‐term HFD consumption caused cognitive decline (pFigure 1).Conclusion: Long‐term HFD consumption, but not LPS alone, caused cognitive decline by increasing peripheral inflammation, disrupting BBB integrity, increasing brain oxidative stress, increasing synaptic engulfment by microglia, and decreasing synaptic plasticity. Microglia are susceptible to impair their function in response to LPS, which potentially worsen brain pathologies in obese condition.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessA single dose of lipopolysaccharide injection exacerbates synaptic engulfment by microglia, and dendritic spine loss in high‐fat diet‐induced obese rats
Background: Diet‐induced obesity can lead to develop endotoxemia and cognitive decline (1). A previous study in Alzheimer’s disease model demonstrated that an increase in the colocalization of C1q, a classical complement protein, and microglia occurred, when those microglia increased synaptic engulfment, resulting in increased synaptic‐pruning process and synaptic loss (2). However, the effects of lipopolysaccharide (LPS) as endotoxin on peripheral inflammation, blood‐brain barrier(BBB) integrity, brain oxidative stress, synaptic engulfment by microglia, synaptic plasticity, and cognitive function in high‐fat diet‐induced obese rats have never been investigated.Method: Sixteen male Wistar rats were randomly assigned to receive either a normal diet (ND, n = 8) or the high‐fat diet (HFD, n = 8) for 12 weeks. All animals in each dietary group were subsequently assigned into 2 subgroups (n = 4 /subgroup) to receive either a single dose of vehicle (1 ml of 0.9% normal saline solution, intraperitoneal (i.p.) injection, or LPS (0.5 mg/kg, i.p.). After the injections for 12‐16 hours, all animals were measured for cognitive function and the blood was collected. Then, animals were sacrificed, and their brains and spleens were obtained for further investigation.Result: All HFD‐fed rats exhibited peripheral inflammation as indicated by increased spleen IL‐1β protein levels, BBB disruption as indicated by the reduction of hippocampal claudia‐5 protein levels, and increased brain oxidative stress as indicated by the increased brain malondialdehyde levels (pFigure 1). Interestingly, LPS‐treated ND‐fed rats and vehicle‐treated HFD‐fed rats equally impaired microglial function by increasing synaptic engulfment as indicated by the increase in C1q colocalized in microglia and the decreased dendritic spine density (pFigure 1). The results demonstrated that these parameters were aggravated in LPS‐treated HFD‐fed rats. Lastly, all HFD‐fed rats decreased the preference index of novel object location and recognition test suggesting long‐term HFD consumption caused cognitive decline (pFigure 1).Conclusion: Long‐term HFD consumption, but not LPS alone, caused cognitive decline by increasing peripheral inflammation, disrupting BBB integrity, increasing brain oxidative stress, increasing synaptic engulfment by microglia, and decreasing synaptic plasticity. Microglia are susceptible to impair their function in response to LPS, which potentially worsen brain pathologies in obese condition.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Acetylcholine Receptor Agonists Exerted Neuroprotection Against Doxorubicin‐Induced Chemobrain
Background: Although doxorubicin has been broadly used in treating a wide range of cancers, it frequently causes a serious neurological consequences referred to as chemobrain in cancer patients. Chemobrain shares several key pathological features with Alzheimer’s disease (AD) including neuroinflammation and Tau pathology. In addition to the inhibition of acetylcholinesterase, the activation of a7nicotinic and muscarinic acetylcholine receptors (a7nAChR and mAChR) using their agonists has been considered an effective therapeutic target against dementia. However, the benefit of intervention with nAChR and mAChR agonists in DOX‐induced chemobrain has never been investigated.Method: Twenty‐five male Wistar rats were assigned to received either (0.9% NSS) or doxorubicin (3 mg/kg; 6 doses) via intraperitoneal injection. Then, doxorubicin‐treated rats were divided into 4 intervention groups to treat with either vehicle, an a7nAChR agonist (PNU‐282987; 3 mg/kg), a mAChR agonist (bethanechol; 12 mg/kg), or a combined treatment of PNU‐282987 and bethanechol via intraperitoneal injection as a concomitant treatment with doxorubicin for a period of 30 days. After completion of the treatment paradigm, cognitive function was evaluated using the novel object location task (NOLT). The hippocampal tissues were dissected to enable further investigation.Result: Systemic administration of doxorubicin impaired long‐term cognitive function in rats as shown by a decreased preference index in the NOLT (Figure A). Furthermore, doxorubicin‐treated rats exhibited neuroinflammation in the hippocampus as demonstrated by an increase in TNF‐a protein expression (Figure B) and an alteration in microglial morphology to a pro‐inflammatory amoeboid‐liked phenotype (Figure C). Notably, injection of doxorubicin markedly reduced the phosphorylation of GSK3b at Ser9 (Figure D) and upregulated the phosphorylation of Tau at Thr181 (Figure E). Also, a decline in the dendritic spine density in the CA1 region was observed in doxorubicin‐treated rats compared with the controls (Figure F). Interestingly, all AChR agonists restored cognitive function in rats in a similar manner by attenuating neuroinflammation and Tau phosphorylation while preserving dendritic spine density (Figure A‐F).Conclusion: Together, activation of AChRs by their agonists protected against the neuropathology of doxorubicin‐induced chemobrain, indicating their potential role as a novel strategy to prevent chemobrain in patients receiving chemotherapy.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessAcetylcholine Receptor Agonists Exerted Neuroprotection Against Doxorubicin‐Induced Chemobrain
Background: Although doxorubicin has been broadly used in treating a wide range of cancers, it frequently causes a serious neurological consequences referred to as chemobrain in cancer patients. Chemobrain shares several key pathological features with Alzheimer’s disease (AD) including neuroinflammation and Tau pathology. In addition to the inhibition of acetylcholinesterase, the activation of a7nicotinic and muscarinic acetylcholine receptors (a7nAChR and mAChR) using their agonists has been considered an effective therapeutic target against dementia. However, the benefit of intervention with nAChR and mAChR agonists in DOX‐induced chemobrain has never been investigated.Method: Twenty‐five male Wistar rats were assigned to received either (0.9% NSS) or doxorubicin (3 mg/kg; 6 doses) via intraperitoneal injection. Then, doxorubicin‐treated rats were divided into 4 intervention groups to treat with either vehicle, an a7nAChR agonist (PNU‐282987; 3 mg/kg), a mAChR agonist (bethanechol; 12 mg/kg), or a combined treatment of PNU‐282987 and bethanechol via intraperitoneal injection as a concomitant treatment with doxorubicin for a period of 30 days. After completion of the treatment paradigm, cognitive function was evaluated using the novel object location task (NOLT). The hippocampal tissues were dissected to enable further investigation.Result: Systemic administration of doxorubicin impaired long‐term cognitive function in rats as shown by a decreased preference index in the NOLT (Figure A). Furthermore, doxorubicin‐treated rats exhibited neuroinflammation in the hippocampus as demonstrated by an increase in TNF‐a protein expression (Figure B) and an alteration in microglial morphology to a pro‐inflammatory amoeboid‐liked phenotype (Figure C). Notably, injection of doxorubicin markedly reduced the phosphorylation of GSK3b at Ser9 (Figure D) and upregulated the phosphorylation of Tau at Thr181 (Figure E). Also, a decline in the dendritic spine density in the CA1 region was observed in doxorubicin‐treated rats compared with the controls (Figure F). Interestingly, all AChR agonists restored cognitive function in rats in a similar manner by attenuating neuroinflammation and Tau phosphorylation while preserving dendritic spine density (Figure A‐F).Conclusion: Together, activation of AChRs by their agonists protected against the neuropathology of doxorubicin‐induced chemobrain, indicating their potential role as a novel strategy to prevent chemobrain in patients receiving chemotherapy.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Pharmacologically targeted mitochondrial fission/fusion performs neuroprotection against trastuzumab‐induced cognitive deficits in rats via suppressing mitochondrial dysfunction and oxidative stress
Background: Trastuzumab (TRZ) has been utilized primarily as a chemotherapeutic treatment for advanced human epidermal growth factor receptor type 2‐expressing malignant tumors. Regardless, TRZ‐associated neurotoxicity has emerged as an adverse clinical complication of oncologic therapy by increasing oxidative stress and damaging mitochondrial function. As the neuroprotective effects of mitochondrial fission inhibitor (MDV) and fusion promoter (M1) have been illustrated for a variety of neurological pathologies, the anti‐neurotoxic mechanisms of MDV and M1 against TRZ are unknown.Method: Twenty male Wistar rats were randomly divided into either the TRZ group (4 mg/kg/day for 7 days, I.P., n = 15) or the control group (CON, n = 5). In the TRZ group, rats also received one of the following co‐treatments: 1) vehicle (VEH, n = 5), 2) MDV (1.2 mg/kg/day, n = 5), or 3) M1 (2 mg/kg/day, n = 5) via I.P. injection for 7 days. Subsequently, novel object location (NOL) and novel object recognition (NOR) tests for long‐term learning and memory were performed. Then, the brain tissue was used for determining mitochondrial functions, and the blood serum was also used to measure the oxidative stress levels.Result: TRZ (the VEH group) increased brain mitochondrial dysfunction and systemic oxidative stress via increasing reactive oxygen species (ROS) production, mitochondrial depolarization, mitochondrial swelling, and serum malondialdehyde levels, respectively, when compared to the CON group (pFigure 1). TRZ (the VEH group) impaired long‐term learning and memory, as indicated by the attenuated percentage preference index of NOL and NOR tests, compared to the CON group (pFigure 1). MDV and M1 co‐therapies exerted neuroprotection by rescuing brain mitochondrial function and systemic oxidative stress, resulting in the restoration of long‐term cognitive parameters (pFigure 1).Conclusion: Targeting brain mitochondrial dynamics could be an effective remedy against TRZ‐induced cognitive impairment in rats via suppressing mitochondrial dysfunction and oxidative stress. Therefore, pharmacological inhibition of mitochondrial fission and promotion of mitochondrial fusion could be a novel anti‐neurotoxicity‐induced by TRZ.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessPharmacologically targeted mitochondrial fission/fusion performs neuroprotection against trastuzumab‐induced cognitive deficits in rats via suppressing mitochondrial dysfunction and oxidative stress
Background: Trastuzumab (TRZ) has been utilized primarily as a chemotherapeutic treatment for advanced human epidermal growth factor receptor type 2‐expressing malignant tumors. Regardless, TRZ‐associated neurotoxicity has emerged as an adverse clinical complication of oncologic therapy by increasing oxidative stress and damaging mitochondrial function. As the neuroprotective effects of mitochondrial fission inhibitor (MDV) and fusion promoter (M1) have been illustrated for a variety of neurological pathologies, the anti‐neurotoxic mechanisms of MDV and M1 against TRZ are unknown.Method: Twenty male Wistar rats were randomly divided into either the TRZ group (4 mg/kg/day for 7 days, I.P., n = 15) or the control group (CON, n = 5). In the TRZ group, rats also received one of the following co‐treatments: 1) vehicle (VEH, n = 5), 2) MDV (1.2 mg/kg/day, n = 5), or 3) M1 (2 mg/kg/day, n = 5) via I.P. injection for 7 days. Subsequently, novel object location (NOL) and novel object recognition (NOR) tests for long‐term learning and memory were performed. Then, the brain tissue was used for determining mitochondrial functions, and the blood serum was also used to measure the oxidative stress levels.Result: TRZ (the VEH group) increased brain mitochondrial dysfunction and systemic oxidative stress via increasing reactive oxygen species (ROS) production, mitochondrial depolarization, mitochondrial swelling, and serum malondialdehyde levels, respectively, when compared to the CON group (pFigure 1). TRZ (the VEH group) impaired long‐term learning and memory, as indicated by the attenuated percentage preference index of NOL and NOR tests, compared to the CON group (pFigure 1). MDV and M1 co‐therapies exerted neuroprotection by rescuing brain mitochondrial function and systemic oxidative stress, resulting in the restoration of long‐term cognitive parameters (pFigure 1).Conclusion: Targeting brain mitochondrial dynamics could be an effective remedy against TRZ‐induced cognitive impairment in rats via suppressing mitochondrial dysfunction and oxidative stress. Therefore, pharmacological inhibition of mitochondrial fission and promotion of mitochondrial fusion could be a novel anti‐neurotoxicity‐induced by TRZ.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Lifestyle Modification Exerts Protection Against Obesity‐Induced Neurodegeneration Via CD147‐Related Mechanism
Background: CD147, also known as extracellular matrix metalloproteinase inducer, is a key mediator of inflammatory and immune responses in various kinds of neurodegenerative disease (1). However, the role of CD147 in obesity‐induced neurodegeneration has not been previously investigated. Therefore, this study aims to investigate the alteration of CD147 expression in the hippocampus of obese rats, both with and without lifestyle modification.Method: Seven‐week‐old male Wistar rats were divided into 4 groups (n = 5 per group), including 1) rats fed with a normal diet for 28 weeks [ND], 2) rats fed with a high‐fat diet (HFD) for 28 weeks [HFD], 3) rats fed with a HFD for 12 weeks followed by 40% caloric restriction for an additional 16 weeks [HFD‐CR], or 4) rats fed with a HFD for 12 weeks followed by exercise plus HFD for an additional 16 weeks [HFD‐EX]. At the end of week 28, cognitive function was determined by a novel object location test. The rats were then euthanized on the following day for molecular studies in the hippocampus.Result: We found that hippocampal CD147 level exerted a strongly negative correlation with the level of cognitive function (Figure A). In addition, CD147 expression and its downstream consequences – p‐NFκB, MMP‐9, and TNF‐α – were upregulated in HFD‐fed rats (Figure B‐E). The HFD‐fed rats also exhibited an increase in activated microglia (CD68), along with decreased blood‐brain barrier protein (claudin‐5), dendritic spine density, and cognitive performance (Figure F‐I). Strikingly, both caloric restriction and exercise effectively reduced the expression of CD147 and its downstream consequences, as well as restored CD68, claudin‐5, dendritic spine density, and cognitive function in HFD‐fed rats (Figure B‐I).Conclusion: Our findings suggested that CD147 is one of the detrimental mediators in obesity‐induced neurodegeneration (Figure J). Interestingly, an attenuation of obesity by lifestyle modification exerts protection against cognitive impairment via CD147‐related mechanisms (Figure J). Therefore, an inhibition of CD147 is considered as a therapeutic target to prevent cognitive impairment in obese individuals. Reference 1. Kaushik DK, Hahn JN, Yong VW. EMMPRIN, an upstream regulator of MMPs, in CNS biology. Matrix Biol. 2015;44‐46:138‐46.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessLifestyle Modification Exerts Protection Against Obesity‐Induced Neurodegeneration Via CD147‐Related Mechanism
Background: CD147, also known as extracellular matrix metalloproteinase inducer, is a key mediator of inflammatory and immune responses in various kinds of neurodegenerative disease (1). However, the role of CD147 in obesity‐induced neurodegeneration has not been previously investigated. Therefore, this study aims to investigate the alteration of CD147 expression in the hippocampus of obese rats, both with and without lifestyle modification.Method: Seven‐week‐old male Wistar rats were divided into 4 groups (n = 5 per group), including 1) rats fed with a normal diet for 28 weeks [ND], 2) rats fed with a high‐fat diet (HFD) for 28 weeks [HFD], 3) rats fed with a HFD for 12 weeks followed by 40% caloric restriction for an additional 16 weeks [HFD‐CR], or 4) rats fed with a HFD for 12 weeks followed by exercise plus HFD for an additional 16 weeks [HFD‐EX]. At the end of week 28, cognitive function was determined by a novel object location test. The rats were then euthanized on the following day for molecular studies in the hippocampus.Result: We found that hippocampal CD147 level exerted a strongly negative correlation with the level of cognitive function (Figure A). In addition, CD147 expression and its downstream consequences – p‐NFκB, MMP‐9, and TNF‐α – were upregulated in HFD‐fed rats (Figure B‐E). The HFD‐fed rats also exhibited an increase in activated microglia (CD68), along with decreased blood‐brain barrier protein (claudin‐5), dendritic spine density, and cognitive performance (Figure F‐I). Strikingly, both caloric restriction and exercise effectively reduced the expression of CD147 and its downstream consequences, as well as restored CD68, claudin‐5, dendritic spine density, and cognitive function in HFD‐fed rats (Figure B‐I).Conclusion: Our findings suggested that CD147 is one of the detrimental mediators in obesity‐induced neurodegeneration (Figure J). Interestingly, an attenuation of obesity by lifestyle modification exerts protection against cognitive impairment via CD147‐related mechanisms (Figure J). Therefore, an inhibition of CD147 is considered as a therapeutic target to prevent cognitive impairment in obese individuals. Reference 1. Kaushik DK, Hahn JN, Yong VW. EMMPRIN, an upstream regulator of MMPs, in CNS biology. Matrix Biol. 2015;44‐46:138‐46.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Lipopolysaccharide aggravates depressive‐like behavior via increasing microglial inflammation, decreasing microglial ramification, and altering tryptophan level in obese rats
Background: Long‐term high‐fat diet consumption has been shown to induce endotoxemia, microglial dysmorphology, and depressive‐like behavior (1, 2). Previous studies demonstrated that the kynurenine pathway of tryptophan metabolism plays an important role on mediating the depressive‐like behavior in response to inflammation (3, 4). However, the effects of lipopolysaccharide as endotoxin on the alterations of microglial profiles/morphologies, changes in brain metabolites, as well as depressive‐like behavior in obese condition have never been investigated.Method: Sixteen male Wistar rats were randomly divided into two groups to fed with either normal diet (ND, n = 8) or the high‐fat diet (HFD, n = 8) for 12 weeks. At week 12, animals in each dietary group were subsequently divided into two subgroups (n = 4 per subgroup) to receive either a single dose of vehicle (1 ml of 0.9% normal saline solution, intraperitoneal (i.p) injection, or lipopolysaccharide (LPS, 0.5 mg/kg, i.p. injection). After the injections for 12‐16 hours, all animals were measured depressive‐like behaviors and blood was collected. Then, animals were sacrificed, and brains were obtained for further molecular investigation.Result: We found that LPS‐treated HFD‐fed rats, not LPS‐treated ND‐fed rats and vehicle‐treated HFD‐fed rats, increased microglial IL‐1β mRNA level (pFigure 1). In addition, LPS‐treated ND‐fed rats and vehicle‐treated HFD‐fed rats significantly decreased microglial ramification as indicated by decreasing branch points, whereas LPS‐treated HFD‐fed rats showed the lowest microglial branch points (pFigure 1). The level of brain tryptophan and depressive‐like behavior increased in both LPS‐treated ND‐fed rats and vehicle‐treated HFD‐fed rats, when compared with those of vehicle‐treated ND‐fed rats (pFigure 1). Interestingly, LPS‐treated HFD‐fed rats showed the highest brain tryptophan level and freezing duration during Force Swimming Test (FST) (pFigure 1).Conclusion: These findings indicate that LPS aggravates depressive‐like behavior in obese condition by increased microglial hyperactivation, and possibly be related to its regulation of kynurenine metabolism.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessLipopolysaccharide aggravates depressive‐like behavior via increasing microglial inflammation, decreasing microglial ramification, and altering tryptophan level in obese rats
Background: Long‐term high‐fat diet consumption has been shown to induce endotoxemia, microglial dysmorphology, and depressive‐like behavior (1, 2). Previous studies demonstrated that the kynurenine pathway of tryptophan metabolism plays an important role on mediating the depressive‐like behavior in response to inflammation (3, 4). However, the effects of lipopolysaccharide as endotoxin on the alterations of microglial profiles/morphologies, changes in brain metabolites, as well as depressive‐like behavior in obese condition have never been investigated.Method: Sixteen male Wistar rats were randomly divided into two groups to fed with either normal diet (ND, n = 8) or the high‐fat diet (HFD, n = 8) for 12 weeks. At week 12, animals in each dietary group were subsequently divided into two subgroups (n = 4 per subgroup) to receive either a single dose of vehicle (1 ml of 0.9% normal saline solution, intraperitoneal (i.p) injection, or lipopolysaccharide (LPS, 0.5 mg/kg, i.p. injection). After the injections for 12‐16 hours, all animals were measured depressive‐like behaviors and blood was collected. Then, animals were sacrificed, and brains were obtained for further molecular investigation.Result: We found that LPS‐treated HFD‐fed rats, not LPS‐treated ND‐fed rats and vehicle‐treated HFD‐fed rats, increased microglial IL‐1β mRNA level (pFigure 1). In addition, LPS‐treated ND‐fed rats and vehicle‐treated HFD‐fed rats significantly decreased microglial ramification as indicated by decreasing branch points, whereas LPS‐treated HFD‐fed rats showed the lowest microglial branch points (pFigure 1). The level of brain tryptophan and depressive‐like behavior increased in both LPS‐treated ND‐fed rats and vehicle‐treated HFD‐fed rats, when compared with those of vehicle‐treated ND‐fed rats (pFigure 1). Interestingly, LPS‐treated HFD‐fed rats showed the highest brain tryptophan level and freezing duration during Force Swimming Test (FST) (pFigure 1).Conclusion: These findings indicate that LPS aggravates depressive‐like behavior in obese condition by increased microglial hyperactivation, and possibly be related to its regulation of kynurenine metabolism.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Administration of mitochondrial fusion promoter during ischemia and at the onset of reperfusion exert neuroprotective effects in rats with cardiac ischemia/reperfusion injury
Background: Acute myocardial infarction (AMI) is one of the fetal cardiovascular diseases and a leading cause of death (1, 2). Our previous study demonstrated that pretreatment of mitochondrial fusion promoter (M1) provided neuroprotective effects on the brain following cardiac ischemia/reperfusion (I/R) injury (3). However, the effects of M1 given during ischemia and M1 given at the onset of reperfusion on brain pathologies following cardiac I/R have never been investigated.Method: Sixteen male Wistar rats were randomly divided into either a sham‐operation (n = 8) or cardiac I/R (n = 24). In the cardiac I/R group, rats were then randomly divided into 3 subgroups, including the I/R operation with vehicle (0.9% sodium chloride solution for 15 minutes before I/R protocol, intravenous (i.v.) injection), the I/R operation with M1 administration during cardiac ischemia (2 mg/kg, 15 minutes after left anterior descending (LAD) coronary artery ligation, i.v. injection), and the I/R operation with M1 administration at the onset of reperfusion group (2 mg/kg at the beginning of reperfusion, i.v. injection). At the end of experimental protocol, rats were sacrificed and brains were obtained for further molecular investigation.Result: The results demonstrated that cardiac I/R increased brain inflammation, caused microglial dysmorphology, caused brain mitochondrial dysfunction, increased tau hyperphosphorylation, and increased brain apoptosis (pFigure 1). M1 given during ischemia and M1 given at the onset of reperfusion effectively attenuated brain pathologies following cardiac I/R by preserving microglial morphology, improving brain mitochondrial function, decreasing tau hyperphosphorylation, and decreasing brain apoptosis (pFigure 1). Interestingly, M1 given during ischemia had better efficacy to suppressing brain inflammation, when compared to M1 given at the onset of reperfusion apoptosis (pFigure 1).Conclusion: These findings suggest the administration of mitochondrial fusion promoter effectively decreased brain pathologies following cardiac I/R. The administration of mitochondrial fusion promoter during ischemia had greater suppression on brain inflammation than administration at the onset of reperfusion. The novel findings obtained from the present study provided the therapeutic strategies which can be translated into clinical settings for cardiac I/R injury.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessAdministration of mitochondrial fusion promoter during ischemia and at the onset of reperfusion exert neuroprotective effects in rats with cardiac ischemia/reperfusion injury
Background: Acute myocardial infarction (AMI) is one of the fetal cardiovascular diseases and a leading cause of death (1, 2). Our previous study demonstrated that pretreatment of mitochondrial fusion promoter (M1) provided neuroprotective effects on the brain following cardiac ischemia/reperfusion (I/R) injury (3). However, the effects of M1 given during ischemia and M1 given at the onset of reperfusion on brain pathologies following cardiac I/R have never been investigated.Method: Sixteen male Wistar rats were randomly divided into either a sham‐operation (n = 8) or cardiac I/R (n = 24). In the cardiac I/R group, rats were then randomly divided into 3 subgroups, including the I/R operation with vehicle (0.9% sodium chloride solution for 15 minutes before I/R protocol, intravenous (i.v.) injection), the I/R operation with M1 administration during cardiac ischemia (2 mg/kg, 15 minutes after left anterior descending (LAD) coronary artery ligation, i.v. injection), and the I/R operation with M1 administration at the onset of reperfusion group (2 mg/kg at the beginning of reperfusion, i.v. injection). At the end of experimental protocol, rats were sacrificed and brains were obtained for further molecular investigation.Result: The results demonstrated that cardiac I/R increased brain inflammation, caused microglial dysmorphology, caused brain mitochondrial dysfunction, increased tau hyperphosphorylation, and increased brain apoptosis (pFigure 1). M1 given during ischemia and M1 given at the onset of reperfusion effectively attenuated brain pathologies following cardiac I/R by preserving microglial morphology, improving brain mitochondrial function, decreasing tau hyperphosphorylation, and decreasing brain apoptosis (pFigure 1). Interestingly, M1 given during ischemia had better efficacy to suppressing brain inflammation, when compared to M1 given at the onset of reperfusion apoptosis (pFigure 1).Conclusion: These findings suggest the administration of mitochondrial fusion promoter effectively decreased brain pathologies following cardiac I/R. The administration of mitochondrial fusion promoter during ischemia had greater suppression on brain inflammation than administration at the onset of reperfusion. The novel findings obtained from the present study provided the therapeutic strategies which can be translated into clinical settings for cardiac I/R injury.
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S1)
Mitochondrial dynamic modulators improve cognitive function in rats with myocardial infarction
Background: Cognitive impairment is the most frequent mental health problem among people with heart failure (HF). Brain pathologies in HF‐induced cognitive impairment are possibly associated with the imbalance of brain mitochondrial dynamics. Therefore, therapeutic interventions targeting mitochondrial dynamics by mitochondrial fission inhibition or mitochondrial fusion enhancement would provide beneficial outcomes to the brain of HF subjects. This study aimed to test whether modulating mitochondrial dynamic improves cognitive function in HF rats via reduced brain mitochondrial dysfunction, and dendritic spine loss.Method: Rats underwent either sham surgery or permanent left anterior descending coronary artery ligation‐induced myocardial infarction (MI). MI rats developed HF with reduced ejection fraction (%LVEF Figure). Treatment with Mdivi‐1 and M1 improved cognitive function similar to enalapril, as indicated by increasing %preference of NOL. Furthermore, all treatments effectively reduced brain mitochondrial ROS levels and hippocampal dendritic spine loss in HF rats (Figure).Conclusion: Mitochondrial fusion inhibitor and mitochondrial fusion improved cognitive function in HF rats through a reduction of mitochondrial ROS levels and preserved dendritic spine density.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S1)
Open AccessMitochondrial dynamic modulators improve cognitive function in rats with myocardial infarction
Background: Cognitive impairment is the most frequent mental health problem among people with heart failure (HF). Brain pathologies in HF‐induced cognitive impairment are possibly associated with the imbalance of brain mitochondrial dynamics. Therefore, therapeutic interventions targeting mitochondrial dynamics by mitochondrial fission inhibition or mitochondrial fusion enhancement would provide beneficial outcomes to the brain of HF subjects. This study aimed to test whether modulating mitochondrial dynamic improves cognitive function in HF rats via reduced brain mitochondrial dysfunction, and dendritic spine loss.Method: Rats underwent either sham surgery or permanent left anterior descending coronary artery ligation‐induced myocardial infarction (MI). MI rats developed HF with reduced ejection fraction (%LVEF Figure). Treatment with Mdivi‐1 and M1 improved cognitive function similar to enalapril, as indicated by increasing %preference of NOL. Furthermore, all treatments effectively reduced brain mitochondrial ROS levels and hippocampal dendritic spine loss in HF rats (Figure).Conclusion: Mitochondrial fusion inhibitor and mitochondrial fusion improved cognitive function in HF rats through a reduction of mitochondrial ROS levels and preserved dendritic spine density.
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S1)
Cyclosorus terminans extract and pioglitazone equally alleviate metabolic disturbance and brain pathology in prediabetic rats
Background: Long‐term high‐fat diet consumption causes prediabetic conditions with brain pathology, as indicated by peripheral and brain insulin resistance, neuroinflammation, neuronal necroptosis, microglial and astrocyte hyperactivation and increased Alzheimer’s disease‐related proteins including amyloid precursor protein (APP). Although pioglitazone, a peroxisome proliferator‐activated receptor (PPAR)‐γ agonist clinically used to treat type 2 diabetes mellitus, has been shown to improve the metabolic and brain functions in prediabetic condition, this drug can lead to several adverse effects. Recently, an in vitro study showed that Cyclosorus terminans extract, which acts as a natural PPAR‐γ agonist, possessed anti‐diabetic and anti‐obesity properties in adipose‐derived stem cells. However, the comparative efficacy of Cyclosorus terminans extract and pioglitazone on metabolic and brain functions in the prediabetic model has not been elucidated.Method: Thirty male rats were fed with either a normal diet (ND) or a high‐fat diet (HFD) for 14 weeks. At week 13, ND‐fed rats received vehicle (NDV; n = 6) for additional 2 weeks. HFD‐fed rats were divided into four subgroups to receive either vehicle (HFV; n = 6), 100 mg/kg/day of Cyclosorus terminans extract (I‐100; n = 6), 200 mg/kg/day of Cyclosorus terminans extract (I‐200; n = 6); or 20 mg/kg/day of pioglitazone (Pio; n = 6) for additional 2 weeks. At the end of experimental period, blood and brains were collected to determine metabolic and brain functions.Result: HFD‐fed rats exhibited a prediabetic condition as characterized by obesity with peripheral insulin resistance. In addition, neuroinflammation, neuronal necroptosis, microglial and astrocyte hyperactivation, and APP expression significantly increased in HFD‐induced prediabetic rats. Cyclosorus terminans extract (100 mg/kg/day) did not attenuate the metabolic disturbance and brain pathologies in HFD‐induced prediabetic rats. Interestingly, 200 mg/kg/day of Cyclosorus terminans extract and pioglitazone equally attenuated peripheral insulin resistance, neuroinflammation, neuronal necroptosis, microglial and astrocyte hyperactivation, and APP expression in HFD‐induced prediabetic rats (P < 0.05, Figure 1).Conclusion: These findings suggest that Cyclosorus terminans extract may be another therapeutic approach for improving metabolic and brain functions in prediabetic patients who have contraindications to pioglitazone therapy.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S1)
Open AccessCyclosorus terminans extract and pioglitazone equally alleviate metabolic disturbance and brain pathology in prediabetic rats
Background: Long‐term high‐fat diet consumption causes prediabetic conditions with brain pathology, as indicated by peripheral and brain insulin resistance, neuroinflammation, neuronal necroptosis, microglial and astrocyte hyperactivation and increased Alzheimer’s disease‐related proteins including amyloid precursor protein (APP). Although pioglitazone, a peroxisome proliferator‐activated receptor (PPAR)‐γ agonist clinically used to treat type 2 diabetes mellitus, has been shown to improve the metabolic and brain functions in prediabetic condition, this drug can lead to several adverse effects. Recently, an in vitro study showed that Cyclosorus terminans extract, which acts as a natural PPAR‐γ agonist, possessed anti‐diabetic and anti‐obesity properties in adipose‐derived stem cells. However, the comparative efficacy of Cyclosorus terminans extract and pioglitazone on metabolic and brain functions in the prediabetic model has not been elucidated.Method: Thirty male rats were fed with either a normal diet (ND) or a high‐fat diet (HFD) for 14 weeks. At week 13, ND‐fed rats received vehicle (NDV; n = 6) for additional 2 weeks. HFD‐fed rats were divided into four subgroups to receive either vehicle (HFV; n = 6), 100 mg/kg/day of Cyclosorus terminans extract (I‐100; n = 6), 200 mg/kg/day of Cyclosorus terminans extract (I‐200; n = 6); or 20 mg/kg/day of pioglitazone (Pio; n = 6) for additional 2 weeks. At the end of experimental period, blood and brains were collected to determine metabolic and brain functions.Result: HFD‐fed rats exhibited a prediabetic condition as characterized by obesity with peripheral insulin resistance. In addition, neuroinflammation, neuronal necroptosis, microglial and astrocyte hyperactivation, and APP expression significantly increased in HFD‐induced prediabetic rats. Cyclosorus terminans extract (100 mg/kg/day) did not attenuate the metabolic disturbance and brain pathologies in HFD‐induced prediabetic rats. Interestingly, 200 mg/kg/day of Cyclosorus terminans extract and pioglitazone equally attenuated peripheral insulin resistance, neuroinflammation, neuronal necroptosis, microglial and astrocyte hyperactivation, and APP expression in HFD‐induced prediabetic rats (P < 0.05, Figure 1).Conclusion: These findings suggest that Cyclosorus terminans extract may be another therapeutic approach for improving metabolic and brain functions in prediabetic patients who have contraindications to pioglitazone therapy.